.Pharmacolibrary.Drugs.ATC.D.D11AH09

Information

Ruxolitinib is an oral Janus kinase (JAK1 and JAK2) inhibitor approved for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It is used to modulate overactive JAK signaling associated with hematological malignancies and is widely used in clinical practice.

Pharmacokinetics

Pharmacokinetics were reported in healthy adult subjects after oral administration; data represent averages from publications and FDA documentation.

References

1. Locatelli, F, et al., & Diaz-de-Heredia, C (2024). Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. The Lancet. Haematology 11(8) e580–e592. DOI:10.1016/S2352-3026(24)00174-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39002551

2. Hurwitz, SJ, et al., & Schinazi, RF (2021). Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. Journal of clinical pharmacology 61(12) 1555–1566. DOI:10.1002/jcph.1930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34169526

3. Chen, X, et al., & Yeleswaram, S (2013). Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). Journal of clinical pharmacology 53(7) 721–730. DOI:10.1002/jcph.102 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23677817

Revisions

• 06/2025 initial generated model